NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced the presentation of a poster at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, taking place on November 3 through 5 in San Diego, CA.
The poster, titled, “Immune Activation with Plinabulin Enhances Anti-tumor Response Combining Radiation with Immune Checkpoint Blockade,” will be presented by Dr. Steven H. Lin, MD., Ph.D., physician-scientist, radiation oncologist and professor who specializes in thoracic malignancies at The University of Texas MD Anderson Cancer Center.
Additional presentation details are as follows:
- Poster Session Date / Time: Saturday, November 4th, 2023, at 9 a.m. to 8:30 p.m. PDT
- Location: San Diego Convention Center, Exhibit Halls A and B1
- Type of Presentation: Poster Presentation
- Abstract No.: 732
About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its pipeline also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring’s subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform and has an initial R&D collaboration with Eli Lilly. Learn more by visiting https://beyondspringpharma.com, and follow us on LinkedIn and Twitter.
Investor Contact:
IR@beyondspringpharma.com
Media Contact:
PR@beyondspringpharma.com
